Celularity Inc (CELU)vsBeiGene, Ltd. (ONC)
CELU
Celularity Inc
$1.21
-4.72%
HEALTHCARE · Cap: $35.18M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 13067% more annual revenue ($5.34B vs $40.58M). ONC leads profitability with a 5.4% profit margin vs -2.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
CELU
Avoid19
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CELU.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
ROE of -63.7% — below average capital efficiency
Revenue declined 43.2%
Earnings declined 61.3%
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : CELU
CELU has a balanced fundamental profile.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : CELU
The primary concerns for CELU are Market Cap, Return on Equity, Revenue Growth.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
CELU profiles as a turnaround stock while ONC is a hypergrowth play — different risk/reward profiles.
CELU carries more volatility with a beta of 0.79 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 19/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Celularity Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Celularity Inc. is a leading biotechnology firm focused on transforming the landscape of regenerative medicine through its unique therapeutic cellular products derived from the placenta. With a strong pipeline of next-generation immunotherapies, including allogeneic off-the-shelf solutions, the company aims to enhance treatment efficacy while reducing associated complications for cancer and other serious illnesses. Driven by an experienced leadership team and strategic partnerships, Celularity is well-positioned to address significant unmet medical needs, solidifying its role as a key player in the rapidly evolving field of advanced therapeutics.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?